News
-
Information
C4U Completed the AMED Stage-Gate Evaluation for Stage 2
-
IP
CRISPR-Cas3 Basic Patent Issued in Europe (European Patent No. 3950942)
-
R&D
Development of Next-Generation T-Cell Gene Editing Technology Using CRISPR-Cas3
-
IP
New Patent Issued in China (Patent No. ZL2021 8 0009880.7)
-
Alliance
C4U Announces the License Agreement with Euglena for CRISPR-Cas3 Technology
-
IP
New Patent Issued in Japan (Patent No. 7802303)
-
R&D
Paper on a new in vivo genome editing technology using CRISPR-Cas3 published in Nature Biotechnology
-
Alliance
C4U Announces the Second License Agreement with RACTHERA for CRISPR-Cas3 Technology
-
IP
New Patent Issued in Europe (European Patent No. 4303310)
-
AllianceR&D
C4U and CiRA Entered Into a New Collaborative Research Agreement